Obeticholic Acid (OCA)

About Intercept Pharmaceuticals

Intercept Pharmaceuticals is a U.S.-based biopharma company that pioneered therapies targeting the Farnesoid X Receptor (FXR) for liver diseases. Its first commercial product, Ocaliva (obeticholic acid), was approved for primary biliary cholangitis (PBC) but was recently voluntarily withdrawn from the market. The company, now part of Alfasigma, is refocusing its pipeline on other severe liver conditions, including severe alcohol-associated hepatitis (sAH), while navigating significant regulatory and commercial challenges.

Therapeutic Areas